Remove Hormones Remove Life Science Remove Regulation
article thumbnail

Neurocrine Biosciences’ Crenessity Approved as First New Treatment in Decades for Rare Genetic Disorder CAH

XTalks

CAH is a group of rare genetic disorders affecting the adrenal glands, which produce essential hormones like cortisol, aldosterone and androgens. The most common form of CAH, 21-hydroxylase deficiency, disrupts hormone production, leading to cortisol deficiency and an overproduction of androgens.

Genetics 116
article thumbnail

Eneboparatide Advances in Hypoparathyroidism Trial: Key Phase III Update

XTalks

Eneboparatide (AZP-3601), an investigational parathyroid hormone 1 receptor (PTH1R) agonist, met its primary endpoint in the CALYPSO Phase III trial, offering new data for adults with chronic hypoparathyroidism. AstraZeneca received eneboparatide during its $1.05 Without proper PTH function, patients may face kidney and bone complications.

Trials 59
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Roche Invests $5.3B in Zealand’s Petrelintide, an Obesity Drug Candidate

XTalks

Amylin, a hormone co-secreted with insulin, plays a key role in regulating appetite by enhancing leptins effects the hormone that signals fullness after eating. Petrelintide, Zealand Pharmas long-acting amylin analog, is currently in Phase II clinical development and is designed for once-weekly subcutaneous injections.

article thumbnail

Obesity-Focused Metsera Launches IPO Amid Much Anticipation

XTalks

a clinical-stage biotech company focused on developing next-gen injectable and oral nutrient-stimulated hormone (NuSH) analog peptides for the treatment of obesity, overweight and related conditions, has priced its initial public offering (IPO) at $18.00 Metsera, Inc., per share, raising $275 million in gross proceeds.

article thumbnail

Aardvark Therapeutics IPO Sets Sights on Satiating Hyperphagia and Extreme Hunger

XTalks

Related: Obesity-Focused Metsera Launches IPO Amid Much Anticipation Aardvarks approach centers on developing novel, small-molecule drugs that harness the bodys natural hunger-regulating mechanisms. In the gut, these receptors prompt the release of hormones such as cholecystokinin and GLP-1, which together signal satiety.

article thumbnail

Thyroid Awareness Month 2024: Increasing Awareness and Exploring New Treatments for Thyroid Diseases

XTalks

The thyroid plays a critical role in the body by producing hormones that regulate metabolism, heart rate and body temperature among others. Types of Thyroid Conditions There are several different thyroid conditions, with each affecting thyroid hormone production or the gland’s structure, leading to a range of health issues.

Hormones 105
article thumbnail

Obesity Drug Petrelintide Advances into Phase IIb

XTalks

Petrelintide, administered once a week under the skin, targets obesity through its action as an amylin analog, a hormone co-secreted with insulin from the pancreas. Amylin helps regulate satiety and slows gastric emptying, which can support weight loss.

Drugs 102